

**Statistical Analysis 1 for Volume of Gadolinium-enhancing Lesions at Baseline, Weeks 12 and 24**

<b>Statistical analysis title</b>	Lesion volume at Week 12		<b>Analysis Type</b>	Other
			<b>Comment</b>	
<b>Statistical analysis description</b>				
<b>Comparison groups or subject analysis sets</b>	Interferon Beta-1b (Betaseron, BAY86-5046)			
<b>Number of subjects in this analysis</b>	38			
<b>Analysis specification</b>	<i>Pre-specified</i>			
<b>Statistical hypothesis test</b>				
<b>P-value</b>	<	Value: 0.0001	<b>Comment</b>	One-sided p-value from Wilcoxon-Signed-Rank-Test for comparing the baseline visit to treatment visits
<b>Method</b> [Required if P-value provided]	<i>Other method name: (specify)</i> Wilcoxon-Signed-Rank test			

**Statistical Analysis 2 for Volume of Gadolinium-enhancing Lesions at Baseline, Weeks 12 and 24**

<b>Statistical analysis title</b>	Lesion volume at Week 24		<b>Analysis Type</b>	Other
			<b>Comment</b>	
<b>Statistical analysis description</b>				
<b>Comparison groups or subject analysis sets</b>	Interferon Beta-1b (Betaseron, BAY86-5046)			
<b>Number of subjects in this analysis</b>	37			
<b>Analysis specification</b>	<i>Pre-specified</i>			
<b>Statistical hypothesis test</b>				
<b>P-value</b>	=	Value: 0.0019	<b>Comment</b>	One-sided p-value from Wilcoxon-Signed-Rank-Test for comparing the baseline visit to treatment visits
<b>Method</b> [Required if P-value provided]	<i>Other method name: (specify)</i> Wilcoxon-Signed-Rank test			